Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
* TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data demonstrates its accuracy in detecting rare genetic diseases * 40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered sta...
Illumina launches TruPath Genome, setting a new standard in genomic insight
* TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow * Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease * Broad Clinical Labs is among first to adopt product, which was previously known as "constellation...
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility
40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 24, 2026 /PRN...
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-mapvariants SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced that Gene...
Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights
At ASHG, an early access customer from the London Health Sciences Center Research Institute demonstrated the power of the 5-base genome for accelerating resolution of rare disease cases Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry,providing researchers with ...
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows Illumin...
Nilesh Shah joins Illumina as Head of Region, AMEA
SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global
leader in DNA sequencing and array-based technologies, announced today the
appointment ofNilesh Shah as Head of Region, AMEA, effective immediately.
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation andglobal market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 25, ...
Macrogen Consortium win tender for National Bio Big Data Project
Illumina is proud to be selected as sequencing technology partner to the Macrogen Consortium. SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Macrogen a global healthcare company that specializes in precision medicine and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and arra...
Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers
Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA ...
Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture
Amid rising agricultural complexity and the push for sustainability, genomics is at the forefront of innovation in breeding practices. SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Illumina (NASDAQ: ILMN) a global leader in genomics, and LGC Biosearch Technologies™, a pioneer in agricultural genomic...
Jenny Zheng joins Illumina as Senior Vice President and General Manager of Greater China
SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- On February 26, 2024, Illumina Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, announced thatJenny Zheng joins Illumina as Senior Vice President and General Manager ofGreater China, and a member of the global executive ma...
Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries
Program aims to address key barriers to genomic sequencing in-country SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to p...
2,800 Singapore Students to Benefit from new STEM Partnership
Year Long Programme with Science Centre Singapore to kick off on World DNA Day as part of Illumina's Future is Bright Initiative. SINGAPORE, April 25, 2023 /PRNewswire/ -- Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) today announced an inaugural partnership with the Science Centr...
Illumina Singapore continues to climb in Best Employers Award Reaching 7th Overall
Illumina is celebrating 25 years of global operations and 15 years in Singapore this April. SINGAPORE, April 18, 2023 /PRNewswire/ -- Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) was honoured today to be ranked 7th overall from 250 companies and 1st in Healthcare Equipment & Ser...
World TB Day 2023: Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa
Transformative Next Generation Sequencing (NGS) Innovation expands access to genomic testing and enables personalized medicine for patients with Tuberculosis (TB) CAPE TOWN, South Africa, March 24, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-bas...
Illumina launches its first product enabling long- and short-read sequencing on one instrument
Early customer data reinforces accuracy and flexibility of novel long-read technology, unlocking access to challenging, low DNA input samples SAN DIEGO, March 15, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced th...
Illumina Among First in the World to Receive Approval of Science-Based Net-Zero Target
The Science Based Targets initiative has validated Illumina's targets to reach Net-Zero greenhouse gas emissions by 2050 SINGAPORE, July 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today it is among the first g...
llumina Among First in the World to Receive Approval of Science-Based Net-Zero Target
The Science Based Targets initiative has validated Illumina's targets to reach Net-Zero greenhouse gas emissions by 2050 SINGAPORE, July 19, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today it is among the first g...
$5M Boost to Innovation in Australia with New Illumina Genomics Lab
New laboratory opens in Melbourne Biomedical Precinct to accelerate the adoption of genomics in healthcare and agriculture inAustralia. MELBOURNE, Australia, Nov. 15, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), the global leader in genomics, today announced the opening of a new, fully eq...
